Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabenazine SCHEMBL13401094 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29383441 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992567 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971241 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29609598 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992566 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL20049732 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971276 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL12394431 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL62026 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20190192524-A1 | Modulators of Caspase-6 | UNIVERSITY OF HAMBURG (DE) | 2019-06-27 | — | — | US | claimed |
| EP-3129027-A1 | MODULATORS OF CASPASE-6 | University of British Columbia (CA) | 2017-02-15 | — | — | EP | claimed |
| EP-2389187-B1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMED RES INST (US) | 2016-11-16 | — | — | EP | claimed |
| US-20160287591-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-10-06 | — | — | US | claimed |
| WO-2016020732-A1 | MODULATORS OF CASPASE-6 | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-02-11 | — | — | WO | claimed |
| WO-2015109107-A1 | TREATMENT AND DIAGNOSIS OF HUNTINGTON'S DISEASE | CAL POLY POMONA FOUNDATION, INC. (US) | 2015-07-23 | — | — | WO | claimed |
| CN-102292094-A | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | — | 2011-12-21 | — | — | CN | claimed |
| EP-2389187-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2011-11-30 | — | — | EP | claimed |
| US-8040867-B2 | Method of multi-antenna wireless data emission, emitter and receiver using the method | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | claimed |
| EP-2338881-A1 | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications | Prexa Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | claimed |
| WO-2010085452-A9 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR - UCLA MEDICAL CENTER (US) | 2011-01-06 | — | — | WO | claimed |
| WO-2010085452-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR - UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | WO | claimed |
| US-20100189818-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | US | claimed |
| CN-101163676-A | Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications | PREXA PHARMACEUTICALS INC (US) | 2008-04-16 | — | — | CN | claimed |
| EP-1853560-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | Psychenomics, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006091697-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | PSYCHENOMICS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC18A2 508/4885KDM4E 2619/4885ABCB11 2959/4885 |
| US-20190192524-A1 | Modulators of Caspase-6 | CASP6, CASP10, CASP2 | SLC18A2 3406/4885KDM4E 2737/4885ABCB11 4688/4885 |
| US-20160287591-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | SLC18A2 1682/4885KDM4E 3465/4885ABCB11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.